TXNRD1 and head and neck cancer: In the realm of head and neck cancer, organoid models have played a crucial role in revealing the synergistic effects of targeting thioredoxin reductase 1 (TrxR1) inhibition in conjunction with anti-PD-1 therapy, thereby emphasizing the potential of ferroptosis induction to enhance therapeutic outcomes in cancer treatment [77].